SARS-CoV-2 Ag
Surveillance Test
High sensitivity pooled antigen testing
The LumiraDx SARS-CoV-2 Ag Surveillance Test is a rapid microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal specimens allowing a pooled testing approach of up to 5 specimens.
Stay vigilant, keep rates low and confidence high
- Lab-comparable results in 12-minutes, The LumiraDx SARS-CoV-2 Ag Surveillance Test delivers fast, accurate, cost-efficient pooled surveillance testing onsite.
- Up to 5 specimens may be pooled and added to a single test strip, without sacrificing sensitivity
- 100.0% positive agreement and 96.6% negative agreement with the LumiraDx SARS-CoV-2 Ag Test
Test workflow
Simple sample prep along with step-by-step on-screen guidance. Results available in 12 minutes.
Rapid, cost-efficient, scalable with cloud based connectivity
Verify that COVID-19 isn’t spreading in your population, quickly implement preventative measures when clusters emerge.
- Faster results deliver peace of mind
- Respond quickly to escalate contact precautions, limiting spread thereby maintaining productivity
More information about the LumiraDx SARS-CoV-2 Ag Surveillance Test
The LumiraDx SARS-CoV-2 Ag Surveillance Test has not been cleared, approved, or authorized by FDA. This test should be used for surveillance purposes (i.e., to inform population or community-level decision-making on de-identified specimens) only. FDA does not regulate surveillance tests.
BetterHealthExperiencesOutcomes
Supporting healthier lives, for individuals, communities and wider society
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.